Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials

Dimopoulos M.A.Moreau P.Iida S.SHANG-YI HUANGTakezako N.Chng W.J.Zahlten-Kumeli A.Sersch M.A.Li J.Huang M.Lee J.H.2021-01-122021-01-1220190925-5710https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070198110&doi=10.1007%2fs12185-019-02704-z&partnerID=40&md5=77846a68bad070af7a2ca1537dfb133ahttps://scholars.lib.ntu.edu.tw/handle/123456789/540523Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trialsjournal article10.1007/s12185-019-02704-z313889322-s2.0-85070198110